The Nonuniformity of Antibody Distribution in the Kidney and its Influence on Dosimetry

Abstract Flynn, A. A., Pedley, R. B., Green, A. J., Dearling, J. L., El-Emir, E., Boxer, G. M., Boden, R. and Begent, R. H. J. The Nonuniformity of Antibody Distribution in the Kidney and its Influence on Dosimetry. Radiat. Res. 159, 182–189 (2003). The therapeutic efficacy of radiolabeled antibody fragments can be limited by nephrotoxicity, particularly when the kidney is the major route of extraction from the circulation. Conventional dose estimates in kidney assume uniform dose deposition, but we have shown increased antibody localization in the cortex after glomerular filtration. The purpose of this study was to measure the radioactivity in cortex relative to medulla for a range of antibodies and to assess the validity of the assumption of uniformity of dose deposition in the whole kidney and in the cortex for these antibodies with a range of radionuclides. Storage phosphor plate technology (radioluminography) was used to acquire images of the distributions of a range of antibodies of various sizes, labeled with 125I, in kidney sections. This allowed the calculation of the antibody concentration in the cortex relative to the medulla. Beta-particle point dose kernels were then used to generate the dose-rate distributions from 14C, 131I, 186Re, 32P and 90Y. The correlation between the actual dose-rate distribution and the corresponding distribution calculated assuming uniform antibody distribution throughout the kidney was used to test the validity of estimating dose by assuming uniformity in the kidney and in the cortex. There was a strong inverse relationship between the ratio of the radioactivity in the cortex relative to that in the medulla and the antibody size. The nonuniformity of dose deposition was greatest with the smallest antibody fragments but became more uniform as the range of the emissions from the radionuclide increased. Furthermore, there was a strong correlation between the actual dose-rate distribution and the distribution when assuming a uniform source in the kidney for intact antibodies along with medium- to long-range radionuclides, but there was no correlation for small antibody fragments with any radioisotope or for short-range radionuclides with any antibody. However, when the cortex was separated from the whole kidney, the correlation between the actual dose-rate distribution and the assumed dose-rate distribution, if the source was uniform, increased significantly. During radioimmunotherapy, the extent of nonuniformity of dose deposition in the kidney depends on the properties of the antibody and radionuclide. For dosimetry estimates, the cortex should be taken as a separate source region when the radiopharmaceutical is small enough to be filtered by the glomerulus.

[1]  F. Greenwood,et al.  THE PREPARATION OF I-131-LABELLED HUMAN GROWTH HORMONE OF HIGH SPECIFIC RADIOACTIVITY. , 1963, The Biochemical journal.

[2]  M. J. Berger,et al.  Distribution of absorbed dose around point sources of electrons and beta particles in water and other media. , 1971, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[3]  B. Sumpio,et al.  Renal handling of proteins in normal and disease states. , 1985, The Quarterly journal of medicine.

[4]  G. T. Rogers,et al.  Mapping epitope characteristics on carcinoembryonic antigen. , 1986, British Journal of Cancer.

[5]  J. Hendry,et al.  The dose-fractionation sensitivity of the kidney; assessment of viable tubule cross-sections at 19 months after X irradiation. , 1993, The British journal of radiology.

[6]  T K Johnson,et al.  Pharmacokinetic modeling. , 1993, Medical physics.

[7]  R. Pedley,et al.  Comparative radioimmunotherapy using intact or F(ab')2 fragments of 131I anti-CEA antibody in a colonic xenograft model. , 1993, British Journal of Cancer.

[8]  R. Owens,et al.  Improved tumor targeting with chemically cross-linked recombinant antibody fragments. , 1994, Cancer research.

[9]  O. Cochet,et al.  Phage libraries for generation of clinically useful antibodies , 1994, The Lancet.

[10]  L. Hope-Stone,et al.  carcinoembryonic antigen: phase I/Il study with comparative biodistribution of intact and F(ab') antibodies , 2007 .

[11]  I. Bernstein,et al.  Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas , 1995, The Lancet.

[12]  Wendy S. Becker,et al.  Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivatives. , 1995, Cancer research.

[13]  J. L. Casey,et al.  Preparation, characterisation and tumour targeting of cross-linked divalent and trivalent anti-tumour Fab' fragments. , 1996, British Journal of Cancer.

[14]  Wendy S. Becker,et al.  Overcoming the nephrotoxicity of radiometal‐labeled immunoconjugates , 1997, Cancer.

[15]  C. Dixon,et al.  Extracellular nucleotides stimulate proliferation in MCF-7 breast cancer cells via P2-purinoceptors. , 1997, British Journal of Cancer.

[16]  G. Adams,et al.  Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies. , 1998, Cancer research.

[17]  J. L. Casey,et al.  Dosimetric evaluation and radioimmunotherapy of anti-tumour multivalent Fab́ fragments , 1999, British Journal of Cancer.

[18]  A J Green,et al.  A comparison of image registration techniques for the correlation of radiolabelled antibody distribution with tumour morphology. , 1999, Physics in medicine and biology.

[19]  J. L. Casey,et al.  A novel technique, using radioluminography, for the measurement of uniformity of radiolabelled antibody distribution in a colorectal cancer xenograft model. , 1999, International journal of radiation oncology, biology, physics.

[20]  J. Kresl,et al.  The employment status of 1995 graduates from radiation oncology training programs in the United States. , 1999, International journal of radiation oncology, biology, physics.

[21]  B. Schultes,et al.  Immunotherapy of human ovarian carcinoma with OvaRex MAb-B43.13 in a human-PBL-SCID/BG mouse model. , 1999, Hybridoma.

[22]  C. Lote Principles of Renal Physiology , 2000, Springer Netherlands.

[23]  A J Green,et al.  A Mouse Model for Calculating the Absorbed Beta-Particle Dose from 131I- and 90Y-Labeled Immunoconjugates, Including a Method for Dealing with Heterogeneity in Kidney and Tumor , 2001, Radiation research.

[24]  R. Pedley,et al.  Effectiveness of radiolabelled antibodies for radio-immunotherapy in a colorectal xenograft model: a comparative study using the linear--quadratic formulation. , 2001, International journal of radiation biology.